Cargando…
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings
BACKGROUND: CER-001 comprises recombinant human apolipoprotein A-I complexed with phospholipids that mimics natural, nascent, pre-β high-density lipoprotein (HDL). We present animal model data showing dose-dependent increases in cholesterol efflux with CER-001 and its subsequent elimination by rever...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394142/ https://www.ncbi.nlm.nih.gov/pubmed/28213743 http://dx.doi.org/10.1007/s40261-017-0506-3 |